^
Association details:
| Biomarker: | POLE EDM |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer
Published date:
02/18/2022
Excerpt:
In conclusion, durvalumab showed promising clinical activity with encouraging response rates and satisfactory survival outcomes in mCRC patients with MSI-H/dMMR or POLE EDM.
DOI:
10.1002/ijc.33966
